Saitoh Masao
Center for Medical Education and Sciences, Graduate School of Medicine, University of Yamanashi, Chuo-city, Yamanashi, Japan.
Semin Cancer Biol. 2023 Dec;97:21-29. doi: 10.1016/j.semcancer.2023.10.001. Epub 2023 Oct 5.
The epithelial-mesenchymal transition (EMT) is one of the processes by which epithelial cells transdifferentiate into mesenchymal cells in the developmental stage, known as "complete EMT." In epithelial cancer, EMT, also termed "partial EMT," is associated with invasion, metastasis, and resistance to therapy, and is elicited by several transcription factors, frequently referred to as EMT transcription factors. Among these transcription factors that regulate EMT, ZEB1/2 (ZEB1 and ZEB2), SNAIL, and TWIST play a prominent role in driving the EMT process (hereafter referred to as "EMT-TFs"). Among these, ZEB1/2 show positive correlation with both expression of mesenchymal marker proteins and the aggressiveness of various carcinomas. On the other hand, TWIST and SNAIL are also correlated with the aggressiveness of carcinomas, but are not highly correlated with mesenchymal marker protein expression. Interestingly, these EMT-TFs are not detected simultaneously in any studied cases of aggressive cancers, except for sarcoma. Thus, only one or some of the EMT-TFs are expressed at high levels in cells of aggressive carcinomas. Expression of EMT-TFs is regulated by transforming growth factor-β (TGF-β), a well-established inducer of EMT, in cooperation with other signaling molecules, such as active RAS signals. The focus of this review is the molecular mechanisms by which EMT-TFs are transcriptionally sustained at sufficiently high levels in cells of aggressive carcinomas and upregulated by TGF-β during cancer progression.
上皮-间质转化(EMT)是上皮细胞在发育阶段转分化为间充质细胞的过程之一,称为“完全EMT”。在上皮性癌中,EMT也被称为“部分EMT”,与侵袭、转移和治疗耐药相关,由几种转录因子引发,这些转录因子常被称为EMT转录因子。在这些调节EMT的转录因子中,ZEB1/2(ZEB1和ZEB2)、SNAIL和TWIST在驱动EMT过程中起重要作用(以下简称“EMT-TFs”)。其中,ZEB1/2与间充质标记蛋白的表达以及各种癌的侵袭性均呈正相关。另一方面,TWIST和SNAIL也与癌的侵袭性相关,但与间充质标记蛋白的表达相关性不高。有趣的是,除肉瘤外,在任何侵袭性癌症的研究病例中均未同时检测到这些EMT-TFs。因此,在侵袭性癌的细胞中,只有一种或某些EMT-TFs高水平表达。EMT-TFs的表达受转化生长因子-β(TGF-β,一种公认的EMT诱导因子)与其他信号分子(如活性RAS信号)协同调节。本综述的重点是在侵袭性癌的细胞中EMT-TFs如何在转录水平上维持足够高的水平,以及在癌症进展过程中如何被TGF-β上调的分子机制。